Stanford history Professor Robert Proctor will speak about the tobacco industry February 18 during a symposium — ”The Sociopolitical Manufacturing of Scientific Ignorance” — at the annual meeting of the American Association for the Advancement of Science in San Francisco.
Preliminary findings from the largest genome scan ever completed in the history of autism research are being published today in Nature Genetics. University of Pittsburgh researchers with a consortium of scientists from across the world contributed to this landmark research endeavor through the Autism Genome Project.
New results in the field of RNA research establish that the RNA splicing factor SF2/ASF can act as a cancer-causing protein by changing the alternative splicing of other genes critical for growth-control of cells.
Tomorrow AAAS Fellow, Robert C. von Borstel will talk about how cancer cell mutation and selection are metaphorically similar to the evolution of a new species.Like the first pregnant finch that landed in the Galapagos, the first cancer cell in a body has to undergo many mutations through many generations to establish itself. But once there, like any newly stabilized species in different ecological niches, cancer is tough to get rid of.
New data, presented at the American Association for the Advancement of Sciences (AAAS), suggests cocoa flavanols may enhance brain blood flow and improve cognitive health.
Researchers from the University of Southern California received approximately $3.4 million from the California Institute for Regenerative Medicine for stem cell research.
Bioengineers and public health researchers at Harvard University have developed a novel spraying method for delivering the most common tuberculosis (TB) vaccine, providing a new low-cost and scaleable technique that offers needle-free delivery and greater stability at room temperature than existing methods.
Talented people often choke under pressure because the distraction caused by stress consumes their working memory, a psychologist at the University of Chicago has found.
Merck & Co., Inc. announced that it has begun to file registrations for ATRIPLA? (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), a once-daily, single tablet regimen for the treatment of HIV-1 infection in adults, with health authorities in those developing countries around the world where many HIV-positive people live.
A mathematical model of disease cycles developed at the University of Michigan shows promise for predicting cholera outbreaks.